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We read with interest the recent publication by Weiss and colleagues, which addressed the 
pitfalls of using next-generation sequencing (NGS) to diagnose PRSS1 variants in chronic 
pancreatitis (CP).1 Specifically, having failed to authenticate an NGS-identified “PRSS1 
c.47C>T (p.Ala16Val) variant” by Sanger sequencing the PRSS1 gene in the supposed 
carrier, they postulated that this artefact could have arisen from sequence 
reads emanating from one of PRSS1’ highly homologous and closely linked (7q34) 
pseudogenes, PRSS3P2. Herein, we address another NGS-related pitfall that contributes to 
confusion in relation to the clinical interpretation of PRSS1 p.Ala16Val. 
p.Ala16Val is the third most commonly detected rare PRSS1 variant in CP; its 
putative pathological involvement is supported by its ability to increase trypsinogen 
autoactivation.2 ClinVar, however, ascribes to it conflicting 
interpretations of pathogenicity (i.e., likely benign (1); pathogenic (3) and uncertain 
significance (2)).3 The main reason for this appears to be its relatively high allele frequency 
(i.e., 0.006607) in all gnomAD v2.1.1 populations.4 Since no p.Ala16Val homozygotes were 
present in gnomAD, its carrier frequency would be 0.0132, which would be ~30 times the 
estimated prevalence of CP (i.e., 30-50/100,000). 
 
To resolve this conundrum, we first surveyed the p.Ala16Val variant data in gnomAD 
v2.1.1. In all four examples of p.Ala16Val heterozygotes whose BAM files were available, a 
mismapping artefact mimicking gene conversion5 can be assumed, bearing in mind the 
following four considerations. First, the p.Ala16Val variant always occurs in association with 
another three variants in close proximity (i.e., the G-T-T-T track in Figure 1A). Second, there 
is a “donor” sequence for these cis-linked variants in another closely linked PRSS1 
pseudogene, TRY7 (trypsinogen D; https://www.ncbi.nlm.nih.gov/gene/?term=try7) (Figure 
1B). Third, allelic ratios of p.Ala16Val in these examples are all <25%, significantly lower 
than the 50% that would be expected for a genuine heterozygous variant. Lastly, despite an 
apparent allele frequency of 0.006607, no p.Ala16Val homozygotes are present in gnomAD 
v2.1.1.   We also surveyed the p.Ala16Val variant data in the French Exome (FrEx) Project 
database,6 obtaining quite similar findings: all “p.Ala16Val” carriers (n = 159; all 
heterozygotes) among the 525 sequenced French individuals carry the aforementioned G-T-
T-T track; additionally, the allelic ratios of p.Ala16Val in these supposed heterozygous 
carriers are unbalanced with a maximum value of 25% (Supplementary Figure S1).  
Finally, we performed a meta-analysis of studies that (i) analyzed p.Ala16Val in both 
patients and controls and (ii) detected the variant at least once by means of Sanger 
sequencing or other conventional mutation screening methods using PRSS1-specific primers. 
The meta-analysis comprised a manual survey of all PRSS1-related publications (until 
December 2018) collated in reference 2, complemented by a keyword search 
(PRSS1 and “chronic pancreatitis”) in PubMed. In cases of overlapping studies from the same 
laboratory, the latest was used for analysis. Three eligible studies were identified;7-9 taken 
together, p.Ala16Val was detected in 18 (1.8%; all heterozygotes) of 983 CP patients 
but was absent from 2288 controls (odds ratio = infinity; p < 0.001) (Table 1).  
Table 1. PRSS1 p.Ala16Val variant in CP patients and controls derived from meta-analysis 





Chen et al.7  2/221 0/400 
Rosendahl et al.8 14/660 0/1758 
Schubert et al.9 2/102 0/130 
Combined 18/983 0/2288 
 
 
In summary, we conclude that the bona fide PRSS1 p.Ala16Val variant is (i) extremely 
rare in the general population and (ii) of genuine pathological significance. This resolves the 
conflicting interpretations of PRSS1 p.Ala16Val in CP and emphasizes the need for careful 
use of gnomAD data in variant assessment.10 
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Figure 1.  PRSS1 p.Ala16Val (c.47C>T) variant as a mismapping artefact mimicking gene 
conversion in gnomAD v.2.1.1. (A) Partial view of genome sequencing data from a 
“heterozygous PRSS1 p.Ala16Val” carrier in gnomAD v2.1.1. (B) Sequence alignment of 
PRSS1 and two of its pseudogenes, PRSS3P2 and TRY7. Note the presence of a “donor” 
sequence for the “p.Ala16Val variant and its three cis-linked variants” in TRY7.  
 
